As House Passes PFAS Action Act, BioLargo Takes Next Step in Commercializing Its PFAS Treatment System

Stock Information for Biolargo Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biolargo Inc

BioLargo Validates Key Performance Metrics of Its Cellinity Battery Energy Storage Technology
Gabelli Funds to Host 2nd Annual PFAS Symposium at The Harvard Club, New York, NY
BioLargo to Host Ribbon-Cutting Event for Battery Pilot Manufacturing Facility
Clyra Medical Technologies, a Subsidiary of BioLargo, Appoints Dr. Steven J. Kavros as Chief Medical Officer
Gabelli Funds to Host 2nd Annual PFAS Symposium at The Harvard Club, New York, NY
BioLargo Earnings Results Webcast and Conference Call on Wednesday, August 14, 2024 - 1:30 PM Pacific Time
BioLargo Achieves Record Quarterly Revenue of $5 Million for Second Quarter of 2024
BioLargo Engineering Increases Ongoing Revenue with Another Air Force Contract

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.